Related references
Note: Only part of the references are listed.Identification of lipid metabolism-related genes as prognostic indicators in papillary thyroid cancer
Shishuai Wen et al.
ACTA BIOCHIMICA ET BIOPHYSICA SINICA (2021)
80MAP17 promotes the tumorigenesis of papillary thyroid carcinoma by reducing the stability of p53
Kun Yu et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2021)
Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Follow-Up
Wenwu Dong et al.
THYROID (2019)
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
Jianfang Liu et al.
CELL (2018)
Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases
Jose M. Garcia-Heredia et al.
MOLECULAR CANCER (2018)
Efficacy of bortezomib in sarcomas with high levels of MAP17 (PDZK1IP1)
Marco Perez et al.
ONCOTARGET (2016)
BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis
Fei Li et al.
ENDOCRINE-RELATED CANCER (2015)
MAP17 (PDZKIP1) Expression Determines Sensitivity to the Proteasomal Inhibitor Bortezomib by Preventing Cytoprotective Autophagy and NFκB Activation in Breast Cancer
Sandra Munoz-Galvan et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Identification of Targets of Twist1 Transcription Factor in Thyroid Cancer Cells
Gennaro Di Maro et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer
Gina M. Howell et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
MAP17 and SGLT1 Protein Expression Levels as Prognostic Markers for Cervical Tumor Patient Survival
Marco Perez et al.
PLOS ONE (2013)
A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up
Raymon H. Grogan et al.
SURGERY (2013)
p38α limits the contribution of MAP17 to cancer progression in breast tumors
M. V. Guijarro et al.
ONCOGENE (2012)
PAPILLARY MICROCARCINOMA IN COMPARISON WITH LARGER PAPILLARY THYROID CARCINOMA IN BRAF(V600E) MUTATION, CLINICOPATHOLOGICAL FEATURES, AND IMMUNOHISTOCHEMICAL FINDINGS
Young Joo Park et al.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK (2010)
Extensive clinical experience - Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma
Cristiana Lupi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
MAP17 overexpression is a common characteristic of carcinomas
Maria V. Guijarro et al.
CARCINOGENESIS (2007)
Interaction of MAP17 with NHERF3/4 induces translocation of the renal Na/Pi IIa transporter to the trans-Golgi
Miguel A. Lanaspa et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer
MZ Xing et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Rat kidney MAP17 induces cotransport of Na-mannose and Na-glucose in Xenopus laevis oocytes
T Blasco et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2003)
The membrane-associated protein pKe#192/MAP17 in human keratinocytes
C Jaeger et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Share Paper
